BioNTech
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Germany · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
An Der Goldgrube 12, Mainz, Rheinland-Pf...Phone Number
+49613190840Website
www.biontech.comRevenue
$3.2 BillionStock Symbol
BNTXIndustry
ZI Rank: 3
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
6
2
2
4
3
3
About BioNTech
BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseasesExplore more
BioNTech Org Chart
UG
Senior Director, Clinical Development Lead
SS
Senior Director
AH
Senior Director & Global Clinical Development...
RC
Senior Director and Business Partner for Qual...
SM
Senior Director, Clinical Science
LA
Senior Director
HH
Director, Clinical Development
NM
Director
DA
Director, Medical Safety
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioNTech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at BioNTech
Check if BioNTech has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when BioNTech launches new products
BioNTech, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if BioNTech is spiking on competitors!
Funding: Get notified immidiatlly once BioNTech has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on BioNTech recently announced quarterly report
Click to see if BioNTech had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
BioNTech is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BioNTech is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BioNTech.
BioNTech financials insights
Gather financial insights about BioNTech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$270M
2019
Series B
$325M
Other Financing Round
$55.7M
2020
Multiple Rounds
$694.8M
BioNTech Tech Stack
A closer look at the technologies used by BioNTech
See more technologies
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Person-Based
Research & Development
BioNTech News & Media
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual Phase 3 melanoma data remains unseen. Here is why the scheduling alone is moving markets and what it signals about what that dataset might show.Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly what kind of bet the market is actually making.BioNTech’s Lung Cancer Drug Shows Signs of a Major Breakthrough
BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the […]BioNTech and OncoC4 report median OS data from RESERVE-003 Phase III trial
In stage I, 87 patients progressed after immunotherapy and chemotherapy and were randomised to two groups.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioNTech
Sign Up For FreeTo access detailed company insights
BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases... Read More
